KFRX06

KFRX06 is a novel, orally delivered small molecule tyrosine kinase inhibitor (TKI) under development by KeifeRx for the treatment of neurodegenerative, neuroinflammatory, and mast cell-associated diseases. The drug is designed to penetrate the brain, induce autophagy, and promote the clearance of disease-causing toxic proteins—mechanisms believed to be beneficial in conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Lewy Body Dementia, frontotemporal dementia, and other immune-related disorders. Preclinical research has demonstrated that KFRX06 inhibits multiple kinases including ABL1 (ABL proto-oncogene 1), FYN (tyrosine-protein kinase FYN), and LRRK2 (leucine-rich repeat serine/threonine-protein kinase 2). These actions are thought to reduce tau hyperphosphorylation and neuronal loss while improving cognitive and behavioral outcomes in relevant models. The intellectual property covering KFRX06 extends through at least 2037[1][4][5].